Firefly Neuroscience (AIFF) EBITDA (2010 - 2026)

Firefly Neuroscience's EBITDA history runs 16 years deep, the most recent figure standing at -$2.0 million for Q1 2026.

• On a quarterly basis, EBITDA rose 2.66% year-over-year to -$2.0 million in Q1 2026; TTM through Mar 2026 was -$8.8 million, a 27.36% increase from a year earlier, with the FY2025 full-year figure at -$8.9 million, up 11.92% from the prior year.
• EBITDA grew to -$2.0 million in Q1 2026 per AIFF's latest filing, from -$2.5 million in the prior quarter.
• Across five years, EBITDA topped out at $493116.0 in Q2 2023 and bottomed at -$6.6 million in Q3 2024.
• The 5-year median for EBITDA is -$1.6 million (2022), against an average of -$1.8 million.
• Across the five-year window, EBITDA tumbled 3062.76% in 2022 and jumped 130.83% in 2023, its largest moves.
• Year by year, EBITDA stood at -$1.0 million in 2022, then slumped by 54.76% to -$1.6 million in 2023, then slumped by 321.83% to -$6.6 million in 2024, then surged by 62.16% to -$2.5 million in 2025, then climbed by 19.63% to -$2.0 million in 2026.
• Per Business Quant, the three latest AIFF EBITDA figures stand at -$2.0 million (Q1 2026), -$2.5 million (Q4 2025), and -$2.7 million (Q3 2025).